Advancements in Stem Cell Transplants and Lemtrada for Senior Patients
A recent study in Sweden found that autologous hematopoietic stem cell transplant (aHSCT) was safe and effective in treating relapsing-remitting multiple sclerosis (RRMS), with nearly three-quarters of patients showing no signs of disease activity after five years. Another study showed that Lemtrada, a disease-modifying therapy, maintained its therapeutic effects on relapse rates, disability, and MRI outcomes over 11 years. Additionally, a survey of neurologists revealed that high-efficacy therapies are often recommended as initial treatment for older adults with MS, and there should be no arbitrary age barrier to aggressive treatment.